PGEN vs. MESO, CNTA, BHC, HRMY, CGON, TARS, JANX, AGIO, NAMS, and IDYA
Should you be buying Precigen stock or one of its competitors? The main competitors of Precigen include Mesoblast (MESO), Centessa Pharmaceuticals (CNTA), Bausch Health Companies (BHC), Harmony Biosciences (HRMY), CG Oncology (CGON), Tarsus Pharmaceuticals (TARS), Janux Therapeutics (JANX), Agios Pharmaceuticals (AGIO), NewAmsterdam Pharma (NAMS), and IDEAYA Biosciences (IDYA). These companies are all part of the "pharmaceutical products" industry.
Precigen vs.
Mesoblast (NASDAQ:MESO) and Precigen (NASDAQ:PGEN) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, community ranking, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings.
In the previous week, Mesoblast and Mesoblast both had 3 articles in the media. Precigen's average media sentiment score of 0.87 beat Mesoblast's score of 0.68 indicating that Precigen is being referred to more favorably in the news media.
Mesoblast has higher earnings, but lower revenue than Precigen.
Mesoblast has a beta of 3.37, meaning that its stock price is 237% more volatile than the S&P 500. Comparatively, Precigen has a beta of 1.66, meaning that its stock price is 66% more volatile than the S&P 500.
Mesoblast has a net margin of 0.00% compared to Precigen's net margin of -3,521.68%. Mesoblast's return on equity of 0.00% beat Precigen's return on equity.
Mesoblast presently has a consensus target price of $18.00, suggesting a potential upside of 9.96%. Precigen has a consensus target price of $7.00, suggesting a potential upside of 266.49%. Given Precigen's higher possible upside, analysts clearly believe Precigen is more favorable than Mesoblast.
1.4% of Mesoblast shares are owned by institutional investors. Comparatively, 33.5% of Precigen shares are owned by institutional investors. 18.8% of Mesoblast shares are owned by insiders. Comparatively, 44.9% of Precigen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Precigen received 24 more outperform votes than Mesoblast when rated by MarketBeat users. However, 70.31% of users gave Mesoblast an outperform vote while only 67.39% of users gave Precigen an outperform vote.
Summary
Mesoblast beats Precigen on 9 of the 16 factors compared between the two stocks.
Get Precigen News Delivered to You Automatically
Sign up to receive the latest news and ratings for PGEN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Precigen Competitors List
Related Companies and Tools
This page (NASDAQ:PGEN) was last updated on 2/21/2025 by MarketBeat.com Staff
